Open AccessAssociation between dopamine and somatostatin receptor expression and pharmacological response to somatostatin analogues in acromegaly
Author(s) -
VenegasMoreno Eva,
VazquezBorrego Mari C.,
Dios Elena,
GrosHerguido Noelia,
FloresMartinez Alvaro,
RiveroCortés Esther,
MadrazoAtutxa Ainara,
Japón Miguel A.,
Luque Raúl M.,
Castaño Justo P.,
Cano David A.,
SotoMoreno Alfonso
Publication year - 2018
Publication title -
journal of cellular and molecular medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.44
H-Index - 130
eISSN - 1582-4934
pISSN - 1582-1838
DOI - 10.1111/jcmm.13440
Subject(s) - acromegaly , somatostatin , endocrinology , somatostatin receptor , medicine , somatostatin receptor 2 , pegvisomant , dopamine , hormone , receptor , somatotropic cell , dopamine receptor , biology , pituitary gland , growth hormone
Acromegaly is a hormonal disorder resulting from excessive growth hormone ( GH ) secretion frequently produced by pituitary adenomas and consequent increase in insulin‐like growth factor 1 ( IGF ‐I). Elevated GH and IGF ‐I levels result in a wide range of somatic, cardiovascular, endocrine, metabolic and gastrointestinal morbidities. Somatostatin analogues ( SSA s) form the basis of medical therapy for acromegaly and are currently used as first‐line treatment or as second‐line therapy in patients undergoing unsuccessful surgery. However, a considerable percentage of patients do not respond to SSA s treatment. Somatostatin receptors ( SSTR 1‐5) and dopamine receptors ( DRD 1‐5) subtypes play critical roles in the regulation of hormone secretion. These receptors are considered important pharmacological targets to inhibit hormone oversecretion. It has been proposed that decreased expression of SSTR s may be associated with poor response to SSA s. Here, we systematically examine SSTR s and DRD s expression in human somatotroph adenomas by quantitative PCR . We observed an association between the response to SSA s treatment and DRD 4, DRD 5, SSTR 1 and SSTR 2 expression. We also examined SSTR expression by immunohistochemistry and found that the immunohistochemical detection of SSTR 2 in particular might be a good predictor of response to SSA s.